The Nuclear factor erythroid 2–related factor 2 (Nrf2) signaling pathway represents one of the most critical cellular defense mechanisms against oxidative stress and neuroinflammation—two hallmarks shared by virtually all neurodegenerative diseases.[1] As the master regulator of the antioxidant response, Nrf2 coordinates the expression of over 500 genes involved in detoxification, glutathione synthesis, drug metabolism, and cellular protection.[2] This mechanistic page explores the Nrf2 pathway's role in neurodegeneration, its dysfunction in disease states, and emerging therapeutic strategies targeting this pathway.
Nrf2 is a basic leucine zipper (bZIP) transcription factor encoded by the NFE2L2 gene located on chromosome 2q31.[3] The protein contains seven highly conserved domains known as Neh (Nrf2-ECH) domains, each serving distinct functions:
| Domain | Name | Function |
|---|---|---|
| Neh1 | CNC-bZIP | Dimerization with small Maf proteins; DNA binding |
| Neh2 | Transactivation domain | Contains KEAP1 interaction motifs (ETGE, DLG) |
| Neh3 | Transactivation domain | Coactivator recruitment (CHD6, BRG1) |
| Neh4 | Transactivation domain | CBP/p300 recruitment |
| Neh5 | Transactivation domain | Transcriptional activation |
| Neh6 | Transactivation domain | β-TrCP-dependent degradation |
| Neh7 | Repression domain | Interaction with RXRα |
Nrf2 regulates the antioxidant response element (ARE) in the promoter regions of numerous protective genes:[4]
Phase II Detoxification Enzymes:
Antioxidant Proteins:
Additional Protective Genes:
Under basal conditions, Nrf2 is sequestered in the cytoplasm by Kelch-like ECH-associated protein 1 (KEAP1), a cysteine-rich adaptor protein that serves as a sensor for oxidative and electrophilic stress.[5] KEAP1 forms a ubiquitin ligase complex with Cullin 3 (CUL3) and Ring-box 1 (RBX1), targeting Nrf2 for continuous ubiquitination and proteasomal degradation.[6]
The KEAP1 protein contains 27 cysteine residues, several of which serve as sensors for electrophiles and oxidants:
When oxidative or electrophilic stress occurs, these cysteine sensors undergo modification, causing a conformational change in KEAP1 that prevents Nrf2 ubiquitination.[7] Stabilized Nrf2 translocates to the nucleus, where it dimerizes with small Maf proteins (MAFK, MAFF, MAFG) and binds to ARE sequences, initiating transcription of protective genes.
Beyond Keap1, Nrf2 is regulated by additional mechanisms:[8]
β-TrCP-mediated degradation — The Neh6 domain contains a phosphodegron recognized by β-transducin repeat-containing protein (β-TrCP), providing a Keap1-independent degradation pathway under certain conditions.
p62/SQSTM1 sequestration — Phosphorylated p62 competes with Nrf2 for Keap1 binding, sequestering Keap1 into autophagosomes and stabilizing Nrf2.[9]
Epigenetic regulation — NFE2L2 promoter methylation can silence Nrf2 expression in some disease states.
Post-translational modifications — Phosphorylation, acetylation, and sumoylation affect Nrf2 activity and localization.
Alzheimer's disease (AD) is characterized by excessive oxidative stress, driven by amyloid-beta (Aβ) plaques, tau pathology, mitochondrial dysfunction, and metal dyshomeostasis.[10] Nrf2 activation provides neuroprotection through multiple mechanisms:
Aβ-Induced Oxidative Damage:
Tau Pathology:
Neuroinflammation:
Studies demonstrate impaired Nrf2 activation in AD brains:
Multiple mechanisms contribute to Nrf2 dysfunction in AD:
Nrf2 activation represents a promising therapeutic approach for AD:
Parkinson's disease (PD) involves progressive loss of dopaminergic neurons in the substantia nigra pars compacta, a region particularly vulnerable to oxidative stress due to:[14]
Mitochondrial Function:
Dopamine Metabolism:
α-Synuclein Pathology:
Several PD-associated genes intersect with Nrf2 signaling:
ALS features rapid motor neuron degeneration driven by oxidative stress, mitochondrial dysfunction, and protein aggregation (SOD1, TDP-43, FUS, C9orf72).[17] Nrf2 dysfunction contributes to disease progression:
Nrf2 activators have shown promise in ALS models:
The hexanucleotide repeat expansion in C9orf72 (the most common genetic cause of familial ALS) affects Nrf2 signaling:
Huntington's disease (HD) involves mutant huntingtin (mHTT) protein that disrupts multiple cellular processes including:[19]
Nrf2 activation strategies show benefit in HD models:
While not a primary neurodegenerative disease, MS provides insights into Nrf2 therapy:
Aging is associated with progressive decline in Nrf2 signaling:[20]
Cellular senescence affects Nrf2 signaling:
Nrf2 plays crucial roles in neuronal survival:
Neuronal Nrf2 activation is particularly important for:
Astrocytic Nrf2 supports neuronal health:
Astrocyte-specific Nrf2 deletion leads to:
Microglial Nrf2 regulates neuroinflammation:
Nrf2 in microglia offers:
Myelin-producing oligodendrocytes require Nrf2:
Nrf2 dysfunction contributes to:
The Nrf2 and NF-κB pathways exhibit cross-inhibition:[21]
Therapeutic implications:
SIRT1 deacetylates Nrf2, enhancing its activity:
The mTOR pathway intersects with Nrf2:
p53 and Nrf2 exhibit complex interactions:
Sulforaphane:[22]
Curcumin:
Resveratrol:
Dimethyl fumarate:
Bardoxolone methyl:
The Nrf2-Keap1 signaling pathway represents one of the most important endogenous defense mechanisms against neurodegeneration. Its dysfunction across Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease makes it an attractive therapeutic target. While direct Nrf2 activators show promise, challenges remain regarding brain penetration, dosing, and long-term safety. The coming years will see multiple clinical trials testing Nrf2-targeted approaches in neurodegenerative diseases.
Cuadrado A, et al. " Nrf2 in neurological diseases. Brain. 2020;143(10):e72". 2020. ↩︎
Kensler TW, et al. " Cell. 2007;129(2):351-360". 2007. ↩︎
" Motohashi H, Yamamoto M. Trends Immunol. 2004;4(10):487-488". 2004. ↩︎
" Raza Z, John A. Biochim Biophys Acta. 2015;1852(7):1315-1329". 2015. ↩︎
Itoh K, et al. " J Biol Chem. 2002;277(40):37588-37595". 2002. ↩︎
Kobayashi A, et al. " Cell Mol Life Sci. 2014;71(19):3879-3894". 2014. ↩︎
Saito T, et al. " Pharmacol Ther. 2015;149:191-198". 2015. ↩︎
Bellezza I, et al. " Redox Biol. 2018;14:417-428". 2018. ↩︎
Komatsu M, et al. " Nat Cell Biol. 2010;12(8):781-794". 2010. ↩︎
" Butterfield DA, Halliwell B. Nat Rev Neurosci. 2019;20(3):148-160". 2019. ↩︎
Schipper HM, et al. " Mol Neurobiol. 2019;56(4):2458-2474". 2019. ↩︎
Jo C, et al. " Neurobiol Aging. 2014;35(7):1565-1575". 2014. ↩︎
Innamorato NG, et al. " Neuropharmacology. 2008;55(8):1284-1290". 2008. ↩︎
Dias V, et al. " Antioxid Redox Signal. 2013;19(7):778-790". 2013. ↩︎
Zhang Y, et al. " Redox Biol. 2015;4:40-47". 2015. ↩︎
Chen PC, et al. " J Neurosci. 2009;29(50):15826-15838". 2009. ↩︎
Vijayakumar D, et al. " Free Radic Biol Med. 2015;88(Pt B):193-204". 2015. ↩︎
Prasad KN, et al. " Neurobiol Aging. 2017;49:31-41". 2017. ↩︎
" Tulsulkar J, Mudhat S. Mol Neurobiol. 2019;56(5):3713-3724". 2019. ↩︎
Zhang M, et al. Nrf2 in brain aging and neurodegeneration: Therapeutic implications. Nat Rev Neurol. 2023. ↩︎
Sanchez-Rodriguez R, et al. Cross-talk between Nrf2 and NF-kappaB in neurodegenerative diseases. Antioxid Redox Signal. 2023. ↩︎
Kraft AD, et al. Nrf2 activation as a therapeutic strategy for Alzheimer's disease. Pharmacol Rev. 2023. ↩︎